Ernexa targets Q4 2026 for first-in-human ovarian cancer trial
Tweet Send to a Friend
Ernexa Therapeutics (NASDAQ: ERNA) released a CEO video discussion on July 14, 2026, outlining the company's plans to submit an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


